Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhiguo Chen, Wei Xie, Desmond Omane Acheampong, Menghuai Xu, Hua He, Mengqi Yang, Chenchen Li, Chen Luo, Min Wang & Juan Zhang. (2016) A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity. Cancer Biology & Therapy 17:2, pages 139-150.
Read now
Read now
Gina M Mantia-Smaldone, Robert P Edwards & Anda M Vlad. (2011) Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Management and Research 3, pages 25-38.
Read now
Read now
Articles from other publishers (8)
Kezia Gaitskell, Ewelina Rogozińska, Sarah Platt, Yifan Chen, Mohamed Abd El Aziz, Abigail Tattersall & Jo Morrison. (2023) Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2023:4.
Crossref
Crossref
Simon Ngigi Mbugua. (2022) Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy. Bioinorganic Chemistry and Applications 2022, pages 1-20.
Crossref
Crossref
X Chen, T Paranjape, C Stahlhut, T McVeigh, F Keane, S Nallur, N Miller, M Kerin, Y Deng, X Yao, H Zhao, J B Weidhaas & F J Slack. (2014) Targeted resequencing of the microRNAome and 3′UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene 34:16, pages 2125-2137.
Crossref
Crossref
Munmun Rahman, Kentaro Nakayama, Tomoka Ishibashi, Masako Ishikawa, Mohammed Rahman, Hiroshi Katagiri, Atsuko Katagiri, Kouji Iida, Yoshihiro Kikuchi & Kohji Miyazaki. (2013) A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. International Journal of Molecular Sciences 14:3, pages 6067-6073.
Crossref
Crossref
Shailendra Giri, Ajay Karakoti, Rondell P. Graham, Jacie L. Maguire, Christopher M. Reilly, Sudipta Seal, Ramandeep Rattan & Viji Shridhar. (2013) Nanoceria: A Rare-Earth Nanoparticle as a Novel Anti-Angiogenic Therapeutic Agent in Ovarian Cancer. PLoS ONE 8:1, pages e54578.
Crossref
Crossref
Kian Behbakht, Michael W. Sill, Kathleen M. Darcy, Stephen C. Rubin, Robert S. Mannel, Steven Waggoner, Russell J. Schilder, Kathy Q. Cai, Andrew K. Godwin & R. Katherine Alpaugh. (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology 123:1, pages 19-26.
Crossref
Crossref
Kezia Gaitskell, Igor Martinek, Andrew Bryant, Sean Kehoe, Shibani Nicum & Jo Morrison. (2011) Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews.
Crossref
Crossref
J. Tate Thigpen, David Alberts, Michael Birrer, Larry Copeland, Robert L. Coleman, Maurie Markman, Robert C. BastJrJr, Eric L. Eisenhauer, Gini Fleming, Paula M. Fracasso, David M. Gershenson, Thomas Herzog, Bradley J. Monk, Robert F. Ozols, Gordon Rustin, Mark F. Brady, Marissa Shrader & Aarati Ranganathan. (2010) Current Challenges and Future Directions in the Management of Ovarian Cancer: Proceedings of the First Global Workshop on Ovarian Cancer. Clinical Ovarian Cancer 3:2, pages 81-97.
Crossref
Crossref